Other PARP inhibitors are being studied; for example, AGO 14699 in locally advanced or metastatic breast cancer and BRCA1/2-mutated ovarian cancer, and AZD2881 in BRCA1/2-mutated ovarian cancer and metastatic TN or BRCA-mutated breast cancer. This evidence concerns the gene BRCA1 and ovarian carcinoma.